Holen Sie sich die Stockscreener-App
30.25
0.95%
-0.44
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$30.69
Offen:
$30.43
24-Stunden-Volumen:
42,795
Relative Volume:
0.05
Marktkapitalisierung:
$1.57B
Einnahmen:
$225.21M
Nettoeinkommen (Verlust:
$-15.70M
KGV:
-89.34
EPS:
-0.3386
Netto-Cashflow:
$-4.78M
1W Leistung:
+4.04%
1M Leistung:
-10.33%
6M Leistung:
+80.95%
1J Leistung:
+74.51%
1-Tages-Spanne:
$30.20
$30.45
1-Wochen-Bereich:
$27.54
$30.74
52-Wochen-Spanne:
$9.215
$36.00
Axogen Inc Stock (AXGN) Company Profile
Firmenname
Axogen Inc
Sektor
Branche
Telefon
(386) 462-6817
Adresse
13631 PROGRESS BLVD., ALACHUA, FL
Compare AXGN vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
30.20 | 1.52B | 225.21M | -15.70M | -4.78M | -0.3386 |
|
ABT
Abbott Laboratories
|
110.19 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
357.80 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
90.08 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.87 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.50 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Wells Fargo | Overweight |
| 2025-12-01 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Lake Street | Buy |
| 2024-07-01 | Eingeleitet | Raymond James | Outperform |
| 2022-11-11 | Fortgesetzt | Jefferies | Buy |
| 2022-05-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-06-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-03-02 | Bestätigt | Lake Street | Buy |
| 2018-01-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Eingeleitet | Jefferies | Buy |
| 2017-11-21 | Bestätigt | Lake Street | Buy |
| 2017-07-31 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Eingeleitet | ROTH Capital | Buy |
| 2016-11-22 | Hochstufung | Lake Street | Hold → Buy |
| 2016-11-07 | Bestätigt | Wedbush | Outperform |
| 2016-11-03 | Herabstufung | Lake Street | Buy → Hold |
| 2016-08-04 | Bestätigt | Wedbush | Outperform |
| 2014-05-14 | Eingeleitet | Dawson James | Buy |
| 2013-10-31 | Bestätigt | Ladenburg Thalmann | Buy |
Alle ansehen
Axogen Inc Aktie (AXGN) Neueste Nachrichten
Axogen at Citizens Life Sciences Conference: Strategic Growth Insights - Investing.com
AxoGen Conference: AVANCE BLA Approval, Debt Paydown Fuel 2026 Growth Target of 18%+ - MarketBeat
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors? - simplywall.st
AxoGen at Leerink Conference: Strategic Growth and Market Expansion - Investing.com India
Chipmakers Recap: Is Axogen Inc in a bullish channel2026 Analyst Calls & Accurate Entry/Exit Alerts - baoquankhu1.vn
Royce & Associates LP Purchases New Shares in AxoGen, Inc. $AXGN - MarketBeat
(AXGN) Risk Channels and Responsive Allocation - Stock Traders Daily
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption - National Today
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference - MarketBeat
AxoGen, Inc. $AXGN Shares Acquired by First Eagle Investment Management LLC - MarketBeat
AXGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Roubaix Capital LLC Purchases New Position in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN) CMO granted 23,000 RSUs and adjusts share holdings - Stock Titan
Axogen (AXGN) innovation chief reports stock awards and tax-share withholding - Stock Titan
Axogen (NASDAQ: AXGN) EVP reports RSU vesting and tax share withholding - Stock Titan
AxoGen, Inc. (NASDAQ:AXGN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Axogen, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Axogen, Inc. Rings the Opening Bell - Nasdaq
Why Axogen (AXGN) Is Down 10.1% After Avance FDA Win and 2026 Guidance Shift - simplywall.st
AxoGen Set to Announce Q4 Earnings on February 24 - Intellectia AI
AXGN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wall Street Zen Downgrades AxoGen (NASDAQ:AXGN) to Buy - MarketBeat
AxoGen, Inc. (AXGN) Stock Analysis: Strong Buy Ratings Signal A 22.88% Upside Potential - DirectorsTalk Interviews
Equity awards and tax share withholding for Axogen (NASDAQ: AXGN) CFO - Stock Titan
Axogen (NASDAQ: AXGN) CEO granted 98,000 RSUs vesting through 2030 - Stock Titan
Axogen (AXGN) Valuation Check After FDA Avance Approval And New 2026 Growth Targets - Sahm
A Look At Axogen (AXGN) Valuation After Recent Share Price Pullback And BLA Expectations - Yahoo Finance
AxoGen Posts Strong Growth and Raises Capital With Offering - The Globe and Mail
Citizens reiterates AxoGen stock rating on strong quarterly revenue By Investing.com - Investing.com Nigeria
AxoGen, Inc. (NASDAQ:AXGN) Q4 2025 Earnings Call Transcript - Insider Monkey
axogen Q4 2025 slides: 21% revenue surge, stock tumbles on costs - Investing.com India
Citizens reiterates AxoGen stock rating on strong quarterly revenue - Investing.com
Axogen Q4: EPS Miss Amid Biologics Transition (NASDAQ:AXGN) - Seeking Alpha
Axogen Inc earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Decoding Axogen Inc (AXGN): A Strategic SWOT Insight - GuruFocus
AxoGen, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
axogen Q4 2025 slides: 21% revenue surge, stock tumbles on costs By Investing.com - Investing.com South Africa
Axogen (AXGN) CFO receives 17,500 RSUs and 17,500 shares, 6,704 withheld for taxes - Stock Titan
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Axogen (AXGN) Q4 2025 Earnings Call Transcript - Nasdaq
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock - The Globe and Mail
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Reven - GuruFocus
Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
CEO Moves: Is Axogen Inc a play on infrastructure spendingMarket Trend Review & High Return Stock Watch Alerts - baoquankhu1.vn
AxoGen Q4 2025 Earnings Call Transcript - MarketBeat
Axogen, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:AXGN) 2026-02-24 - Seeking Alpha
AxoGen Q4 Earnings Call Highlights - MarketBeat
AXGN Stock: Citizens Maintains Rating, Raises Price Target to $4 - GuruFocus
AxoGen (NASDAQ:AXGN) Shares Gap Down on Disappointing Earnings - MarketBeat
AXGN: 2025 saw 20% revenue growth, FDA BLA approval, and strong outlook for 2026 with 18%+ growth - TradingView
Earnings call transcript: AxoGen Q4 2025 beats forecasts, stock dips By Investing.com - Investing.com India
Finanzdaten der Axogen Inc-Aktie (AXGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
1.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):